12
|
Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 2014; 19:1169-78. [PMID: 25223462 DOI: 10.1634/theoncologist.2014-0190] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC). We present the results of this study in Chinese patients. METHODS In a multicenter, open-label, randomized, phase III study (NCT00471965), 371 patients (279 patients from the People's Republic of China) were randomized 1:1 to receive either FOLFOX4 or doxorubicin until disease progression, intolerable toxicity, death, or surgical resection. RESULTS Baseline characteristics of the Chinese patients enrolled in the study were similar for the 2 treatment groups and in comparison with the whole EACH cohort. Median OS at the prespecified time point of treatment was 5.7 months with FOLFOX4 and 4.3 months with doxorubicin (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.55-0.98; p = .03). At the end of the follow-up period, median OS was 5.9 months with FOLFOX4 and 4.3 months with doxorubicin (HR: 0.75; 95% CI: 0.58-0.98; p = .03). Median PFS was 2.4 months and 1.7 months in the FOLFOX4 and doxorubicin groups, respectively (HR: 0.55; 95% CI: 0.45-0.78; p = .0002). The response rate (RR) and disease control rate (DCR) were significantly higher in the FOLFOX4 group than in the doxorubicin group (RR: 8.6% vs. 1.4%, p = .006; DCR: 47.1% vs. 26.6%, p = .0004). Hematological toxicity was more frequently reported in the FOLFOX4 group. CONCLUSION For Chinese HCC patients enrolled in the EACH study, FOLFOX4 significantly improved the RR and DCR and prolonged survival compared with doxorubicin. Systemic chemotherapy with oxaliplatin-based regimens may play an important role in the treatment of Chinese patients with advanced HCC.
Collapse
Affiliation(s)
- Shukui Qin
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Ying Cheng
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Jun Liang
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Lin Shen
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Yuxian Bai
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Jianfeng Li
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Jia Fan
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Lijian Liang
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Yaqi Zhang
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Gang Wu
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Kun-Ming Rau
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Tsai-Shen Yang
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Zhixiang Jian
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Houjie Liang
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| | - Yan Sun
- People's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China
| |
Collapse
|